Metrics cut 1
- SteriPort Line 3 commercial production delayed to last week of August 2026 (Q2 FY27) from originally targeted Q1 FY27 (April–June 2026)
Event Participants
Executives (2)
Bhavesh Patel — Managing Director, Member; Paras Mehta — Chief Financial Officer
Analysts (10)
Avnish Burman (Vaikarya); Deeya Jain (FIA Capital); Divya Duggar (VG SPL); Mukesh Panjwani (WC Securities); Nikhil Agarwal (Alpha AIF); Nikhil Gupta (Vayu Capital); Preet Shah (Blue Star Capital); Saket Saurabh (Sagari Capital); Shivam Shah (Zen Nivesh); Urmish Shah (Moneywisers)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹69 crore | +5% YoY; growth supported by improved product mix and better price realizations despite Middle East crisis slowdown |
| EBITDA | ~₹15 crore | ~22% margin; sustained despite raw material price pressure, higher employee cost, and pre-commissioning overheads for new facilities |
| SteriPort revenue share | ~44% of revenue | Continued strong customer acceptance; ISBM tech platform capturing hospital demand across oncology, critical care, anesthesia, pediatrics |
| SVP revenue share | ~20% of FY26 revenue | Export-centric business (90% exports, 60%+ from advanced/semi-advanced markets); new facility expected Q4 FY27 |
| SteriPort capacity | 6.6 → 12 crore bottles/year | Capacity doubling for Line 3; commissioning delayed to Q2 FY27 due to civil construction — FDA plans approved, validation by Aug 18, commercial production by Aug 24–25 |
| Captive solar plant | 10.8 MW | Commissioned June 2026; saving |
| Incremental depreciation (FY27 vs FY26) | ~₹6 crore annually | Includes Line 3 (~₹4.5 crore), SVP, and solar plant depreciation |
| Interest expense | FY27: ~₹21 crore; FY28: ~₹18–19 crore | Declining trajectory; marginal Q1 uptick from solar capex debt; debt reducing ~₹30–35 crore annually |
| Effective tax rate | ~26% | Book tax rate for FY27 and FY28 |
Geographic & Segment Commentary
Domestic SteriPort (LVP/IV Fluids): Primary FY27 growth driver; India-centric, no regulatory hurdles with strong hospital penetration among intensivists, pediatricians, oncologists, cardiologists. Segment faces competition from Otsuka (Japan), Fresenius Kabi (Germany), B. Braun (major cities only), and AcuLife (limited presence). Existing facility at 90–95% utilization; Line 3 commissioning expected to materially boost volumes from Q3 FY27.
Export SVP (Small Volume Parenterals): ~20% of FY26 revenue, 90% export-driven with 60%+ from advanced markets (UK, Ireland, Australia, Canada). Focus on inhalation solutions, ophthalmics, and preservative-free unit doses for European markets. New facility commissioning in Q4 FY27 (March 2027); FAT scheduled in USA in November 2026. Target: 60–70% of SVP revenue from advanced markets going forward.
Company-Specific & Strategic Commentary
SteriPort Line 3 Expansion: ~₹90 crore total capex, ₹80 crore spent to date. FDA plans approved, validation completing by Aug 18, FDA inspection Aug 21, commercial production last week of August. Line dedicated to 500 mL platform, enabling single-SKU production on existing line. Peak annualized revenue ₹120 crore; incremental ROIC 16–17%. Additional depreciation ₹4.5 crore annually.
SVP Facility & F&D Pipeline: ₹40 crore capex (₹7 crore spent); commissioning Q4 FY27. Dedicated F&D team of 5 scientists driving 20-product pipeline (7–8 ophthalmic products, inhalation, diluents). First inhalation product commercial by September 15. SVP facility incremental ROIC ~14–15%.
Captive Solar Power: 10.8 MW plant commissioned June 2026, saving ~₹75 lakh/month. Combined with SteriPort commissioning, expected to drive 4–5% consolidated EBITDA margin expansion (including ₹9 crore solar saving).
Cost Optimization & Price Discipline: Polymer price spike of 70–80% (2-month duration) partially mitigated via ₹1.50 price increase vs. ~₹2.25 polymer cost impact. Management expects full recovery over two quarters as prices normalize within 2–3 months.
Diversification Beyond Plastic: Management exploring glass-based packaging, lyophilized injectables, cartridges, and IV bag lines; clarity expected in 6 months (Dec–Jan). Long-term strategy: stay wedded to sterile dosage forms only, expanding beyond BFS plastic constraints. SVP gradually transitioning toward CDMO / finished-dosage injectables profile.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue | ~₹370 crore (without SVP) | Based on SteriPort contributing ~₹70 crore over remaining 7 months; excludes SVP which commissions in Q4 |
| FY28 Revenue (peak) | ~₹425 crore | Assumes all capacities live (SteriPort + SVP); management noted "roughly" |
| FY28 EBITDA Margin | ~25–26% | ~1% plus/minus for FY27 and FY28; driven by operating leverage, solar savings, favorable product mix |
| SteriPort EBITDA Margin Expansion | +4–5% (consolidated, incl. solar ₹9 crore savings) | Drivers: overhead absorption with Line 3, dedicated 500 mL SKU line improving output efficiency |
| SteriPort Line 3 Commercial Production | Last week of August 2026 | FDA inspection scheduled Aug 21; validation complete by Aug 18 |
| SVP Facility Commissioning | Q4 FY27 (Feb–Mar 2027) | FAT in USA November 2026; minimal civil work reduces timeline risk |
| Interest Expense | FY27: ~₹21 crore; FY28: ~₹18–19 crore | Declining as debt amortizes; solar capex spike in Q1 was temporary |
| Effective Tax Rate | ~26% | Book tax rate for FY27 and FY28 |
Risks & Constraints
| Risk | Context |
|---|---|
| Polymer Price Volatility | Prices spiked 70–80% over 2 months due to Iran war / Middle East crisis; impact ~₹2.25 per unit vs. ₹1.50 price correction taken. Management expects ~70% absorption in current quarter with remainder in following quarter; prices now ~80% recovered to normal levels. |
| SteriPort Line 3 Commissioning Delay | Originally targeted Q1 FY27; delayed 5 months due to civil construction. Overheads absorbed without revenue contribution during delay; Q2 FY27 impact limited to one month (September). |
| FDA Regulatory Timeline | FDA inspection scheduled Aug 21; any rescheduling could push validation/commercial production beyond August 24–25 target. PIC/S guideline changes (updated Annexure 1) require hardware corrections for BFS operations before approvals. |
| Geopolitical / Middle East Slowdown | Iran war situation caused business slowdown across segments during Q1; polymer supply chain volatility and price spike were direct consequences. Oil price softening expected to normalize polymer prices within 2–3 months. |
| Competition from MNCs | Otsuka, Fresenius Kabi, B. Braun, AcuLife active in special-feature plastic container segment; MNCs confine mostly to major cities, but their scale and brand presence limit Amanta's pricing power in institutional tenders. |
| Export Regulatory Approvals | SVP advanced-market entry (UK, EU, Australia, Canada) requires prolonged product approvals and regulatory inspections; timeline risk remains despite FAT schedule. |
Q&A Highlights
SteriPort Line 3: Revenue, Depreciation & Margin Expansion
Question: Peak revenue of ₹110–120 crore from Line 3 — realized within 12 months of commissioning? (Avnish Burman)
Answer: Yes, ₹120 crore is an annualized figure; expected within 12 months from commissioning. Incremental depreciation from Line 3 is ₹4.5 crore annually; total additional depreciation vs FY26 including SVP and solar is ~₹6 crore. Margin expansion of 4–5% includes solar benefit (₹9 crore savings) and overhead absorption — combined target. (Bhavesh Patel, Paras Mehta)
Question: Is the 4–5% margin expansion on consolidated EBITDA basis? (Avnish Burman)
Answer: Yes, consolidated basis, with noted that ₹9 crore solar saving alone contributes ~1.5% to margin expansion. Product mix improvement from dedicated 500 mL SKU line also adds favorably. (Bhavesh Patel)
Cost Pressures & Polymer Pricing
Question: What were the specific cost pressures in the quarter? (Nikhil Agarwal)
Answer: Polymer price spike from Middle East crisis (~₹2.25 impact per unit) and pre-commissioning overheads for SteriPort Line 3 (manpower hired ahead of commercial production, one quarter of overheads absorbed without revenue contribution). Polymer prices have already softened ~80% from spike levels and expected to normalize within 2–3 months. (Bhavesh Patel)
Question: How do you mitigate polymer price fluctuations — is there a pass-through mechanism? (Urmish Shah)
Answer: Price correction of ₹1.50 taken vs. ~₹2.25 polymer impact. Price increases are stickier than input costs — even after normalization, ~₹1+ remains in pricing. Recovery spills over two quarters; annual basis absorption is achievable. (Bhavesh Patel)
SVP Facility & R&D Pipeline
- Question: When will SVP facility commercialize? (Nikhil Agarwal)
- Answer: Feb–Mar 2027; FAT scheduled in USA in second week of November, site arrival December, two months for installation. Minimal civil work reduces timeline risk. No significant new hiring needed — F&D team already onboarded (5 scientists); first inhalation product commercializing by September 15. (Bhavesh Patel)
FY27/FY28 Revenue and Margin Guidance
- Question: What is peak revenue at full utilization? (Preet Shah)
- Answer: FY27: ~₹370 crore without SVP (SteriPort contributing ~₹70 crore in remaining 7 months). FY28 at all capacities live: ~₹425 crore. EBITDA margins for FY28: 25–26%, ~1% plus/minus for FY27 and FY28. (Bhavesh Patel, Paras Mehta)
Competitive Landscape
- Question: Who are the competitors in India? (Divya Duggar)
- Answer: In the special-feature plastic container segment: Otsuka (Japan MNC), Fresenius Kabi (Germany MNC), B. Braun (major cities only), AcuLife (limited presence). Amanta differentiates on national reach and specialized formulation capabilities. (Bhavesh Patel)
Growth Drivers Beyond FY27
- Question: What are the next major growth drivers after SteriPort and SVP expansions? (Shivam Shah)
- Answer: SVP inhalation products, ophthalmics, and diluents for advanced markets. 20-product pipeline with 5 scientists; one inhalation product commercial by mid-September. Post-2027: exploring glass-based packaging, lyophilized injectables, and CDMO-style finished-dose injectables. Sterile dosage form remains the core focus. (Bhavesh Patel)
Working Capital & Debt Reduction
- Question: Net working capital of 141 days and debt-to-equity of 1.06 — can these improve? (Urmish Shah)
- Answer: Additional debt taken for solar capex (₹75 lakh/month savings, no-brainer investment) skewed trajectory; excluding that, downward trend is faster. Debt reducing ₹30–35 crore annually. Working capital cycle is structurally longish due to 20–25 day quarantine requirements for injectables — typical for IV fluid/injectable manufacturers. (Bhavesh Patel)
CapEx Investment Details
- Question: How much invested in SteriPort Line 3 and SVP? (Deeya Jain)
- Answer: SteriPort Line 3: ₹90 crore total capex, ₹80 crore spent. SVP: ₹40 crore total capex, ₹7 crore spent, remainder over coming quarters. (Paras Mehta)
ROIC Validation & Tax Rate
- Question: Confirm incremental ROIC of 16–17% on SteriPort and 13–14% on SVP; what tax rate to assume? (Avnish Burman)
- Answer: ROIC numbers broadly correct; SVP around 14–15%. ROIC appears modest due to rising capital base from IPO share premium and internal accruals — profitability speed must outpace capital employed growth. Effective tax rate: 26%. Interest: ~₹21 crore FY27, ~₹18–19 crore FY28. (Paras Mehta)
Long-Term Vision & R&D Spend
- Question: Is there a ₹1,000 crore revenue vision over 4–5 years? (Nikhil Gupta)
- Answer: No fixed rupee target; vision anchored on sterile dosage form only. Will expand beyond plastic packaging into glass, IV bags, lyophilized, and cartridges. Innovation tracking in process solutions and drug delivery mechanisms. (Bhavesh Patel)
Key Takeaway
Amanta Healthcare delivered a stable Q1 FY27 with revenue of ₹69 crore (+5% YoY) and EBITDA margin of ~22%, absorbing polymer price spikes, Middle East crisis headwinds, and pre-commissioning overheads for delayed SteriPort Line 3. The company's strategic focus centers on three pillars: SteriPort capacity doubling (6.6→12 crore bottles, ₹90 crore capex, FDA approval secured, commercial production by late August), SVP export expansion targeting inhalation/ophthalmic products for advanced markets (₹40 crore capex, commissioning Q4 FY27, 20-product F&D pipeline), and the 10.8 MW captive solar plant delivering ~₹9 crore annual savings. Management guided FY27 revenue of ~₹370 crore and FY28 peak revenue of ~₹425 crore with 25–26% EBITDA margins. Key watch points: SteriPort Line 3 FDA inspection on August 21, successful SVP FAT in November, sustained polymer price normalization, and execution of the 4–5% margin expansion plan — all of which will determine whether Amanta delivers on its promised operating leverage over the next two quarters.